Edition:
United Kingdom

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

58.47USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$58.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,878
52-wk High
$59.54
52-wk Low
$32.62

Latest Key Developments (Source: Significant Developments)

Acceleron Pharma Inc - QTRLY Loss Per Share $0.63
Thursday, 2 Aug 2018 

Acceleron Pharma Inc ::ACCELERON REPORTS SECOND QUARTER 2018 OPERATING AND FINANCIAL RESULTS.ACCELERON PHARMA - BELIEVES EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND PROJECTED OPERATING REQUIREMENTS INTO 2021.ACCELERON PHARMA INC - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2018 WERE $332.3 MILLION..ACCELERON PHARMA INC - QTRLY LOSS PER SHARE $0.63.ACCELERON PHARMA INC - COLLABORATION REVENUE FOR Q2 WAS $3.7 MILLION.  Full Article

Acceleron Announces Prelim Results From Phase 2 Charcot-Marie-Tooth Disease Trial
Monday, 23 Jul 2018 

July 23 (Reuters) - Acceleron Pharma Inc ::ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE AT THE 2018 ANNUAL MEETING OF THE PERIPHERAL NERVE SOCIETY.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE AT THE 2018 ANNUAL MEETING OF THE PERIPHERAL NERVE SOCIETY.ACCELERON PHARMA INC - MEAN TOTAL MUSCLE VOLUME INCREASES OF MORE THAN 12% SEEN IN TIBIALIS ANTERIOR.ACCELERON PHARMA INC - COMPANY PLANS TO INITIATE PART 2 OF CMT PHASE 2 TRIAL IN Q3 OF 2018.ACCELERON PHARMA INC - PRELIMINARY RESULTS EXPECTED BY END OF 2019 FOR PART 2 CMT PHASE 2 TRIAL.  Full Article

Acceleron Receives FDA Orphan Drug Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy
Thursday, 12 Jul 2018 

July 12 (Reuters) - Acceleron Pharma Inc ::ACCELERON RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY.ACCELERON RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY.ACCELERON PHARMA INC - TO SHARE PART 2 RESULTS FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY LATER NEXT YEAR.  Full Article

Celgene And Acceleron says Luspatercept Achieved main goals in study
Monday, 9 Jul 2018 

July 10 (Reuters) - Celgene Corp ::CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III ‘BELIEVE’ STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA.CELGENE CORP - RESULTS SHOWED A SIGNIFICANT REDUCTION IN TRANSFUSION BURDEN COMPARED TO PLACEBO.CELGENE CORP - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.CELGENE CORP - SAFETY PROFILE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - ADVERSE EVENTS OBSERVED IN STUDY WERE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - DATA FROM BELIEVE AND MEDALIST WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING IN 2018.  Full Article

Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy
Tuesday, 1 May 2018 

May 1 (Reuters) - Acceleron Pharma Inc ::ACCELERON RECEIVES FDA FAST TRACK DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD).  Full Article

Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Acceleron Pharma Inc ::ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY.  Full Article

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Acceleron Begins Phase 2 Trial Of Pulmonary Arterial Hypertension Treatment

* ACCELERON ANNOUNCES INITIATION OF PULSAR PHASE 2 TRIAL OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION